Univest
Univest
  • Markets

Balaxi Pharmaceuticals Ltd. (BALAXI) Share Price rises 16.4% as market cap stands at Rs 146.13 Cr

  • September 2, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Balaxi Pharmaceuticals Ltd. Share Price
Balaxi Pharmaceuticals Ltd. (BALAXI) share price rose to Rs 36.84 today, up 16.4% from the previous close. Market cap was Rs 146.13 crore.

Balaxi Pharmaceuticals Ltd. Share Price is higher today at Rs 36.84, up 16.4% from the previous close of Rs 31.65, with market capitalisation at Rs 146.13 Cr. According to latest Univest figures, the move is confirmed, but no company-specific catalyst is established. The latest Univest figures also show that the stock opened at Rs 31.80, touched a high of Rs 36.90 and a low of Rs 31.80, keeping the current Balaxi Pharmaceuticals Ltd. Share Price near the upper end of today’s range. For readers tracking Balaxi Pharmaceuticals Ltd. Share Price Today, the main point is simple: the stock is trading meaningfully above the prior close while the verified data keeps the reason for the rise open. Investors monitoring Balaxi Pharmaceuticals Ltd. Stock News can use this as a price-action starting point, then look next at valuation and sector comparisons.

Table of Contents

Toggle
  • Balaxi Pharmaceuticals Ltd. Share Price Today: Price Action Analysis
  • Balaxi Pharmaceuticals Ltd. (BALAXI) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Balaxi Pharmaceuticals Ltd.
  • About Balaxi Pharmaceuticals Ltd.
  • Frequently Asked Questions
    • Why is Balaxi Pharmaceuticals Ltd. Share Price rising today?
    • What is Balaxi Pharmaceuticals Ltd. Share Price today?
    • What is the market capitalisation of Balaxi Pharmaceuticals Ltd.?
    • How does Balaxi Pharmaceuticals Ltd. Share Price compare with the sector?
    • What is Balaxi Pharmaceuticals Ltd. P/E ratio?
    • What is Balaxi Pharmaceuticals Ltd. P/B ratio?
    • What do ROE and ROCE show for Balaxi Pharmaceuticals Ltd.?
    • Does Balaxi Pharmaceuticals Ltd. pay a dividend yield?
  • Track Balaxi Pharmaceuticals Ltd. Share Price on Univest

Balaxi Pharmaceuticals Ltd. Share Price Today: Price Action Analysis

Metric Value
Current Price Rs 36.84
Previous Close Rs 31.65
Today's Move Rs 5.19 (+16.4%)
Open Rs 31.8
High Rs 36.9
Low Rs 31.8
Market Capitalisation Rs 146.13 crore
Market Cap Category Micro Cap

Balaxi Pharmaceuticals Ltd. (BALAXI) rose to Rs 36.84 from the previous close of Rs 31.65, a move of Rs 5.19 or 16.4%. The stock opened at Rs 31.8, reached a high of Rs 36.9, recorded a low of Rs 31.8.

The Balaxi Pharmaceuticals Ltd. Share Price is trading at Rs 36.84 after a gain of Rs 5.19, or 16.4%, versus the previous close. The Balaxi Pharmaceuticals Ltd. Share Price opened at Rs 31.80, moved between Rs 31.80 and Rs 36.90, and stayed close to the day’s high. That makes today’s Balaxi Pharmaceuticals Ltd. Share Price Today action a clear price rise rather than a narrow drift. The market capitalisation of Rs 146.13 Cr places the stock at a level that investors can track alongside its day change and range. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. For readers checking Balaxi Pharmaceuticals Ltd. Share Price Live, the next step is to connect this move with fundamentals and valuation context.

Balaxi Pharmaceuticals Ltd. (BALAXI) Fundamental Analysis

Metric Value
Market Capitalisation Rs 146.13 crore
P/E Ratio 51.93x
P/B Ratio 0.69x
ROE 0.59%
ROCE 3.48%
EPS Rs 0.61
Book Value Per Share Rs 46.04
Dividend Yield 0%

Balaxi Pharmaceuticals Ltd. (BALAXI) fundamental metrics show P/E 51.93x, P/B 0.69x, ROE 0.59%, ROCE 3.48%. Read together, these ratios describe the company’s position rather than a recommendation.

Balaxi Pharmaceuticals Ltd. has a market capitalisation of Rs 146.13 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 51.93x, P/B at 0.69x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 0.59% and ROCE of 3.48%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 0.61, book value per share of Rs 46.04, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 22.63x, median ROE of 4.09%, median ROCE of 6.07%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric Value
Sector Trading
Industry Trading
Benchmark Scope same industry
Company P/E Ratio 51.93x
Benchmark Median P/E 22.63x
Benchmark Average P/E 90.95x
Benchmark P/E Range 0.1x to 4,774.33x
Company P/B Ratio 0.69x
Benchmark Median P/B 1.35x
Company ROE 0.59%
Benchmark Median ROE 4.09%
Company ROCE 3.48%
Benchmark Median ROCE 6.07%
Company Market Capitalisation Rs 146.13 crore
Benchmark Median Market Cap Rs 53.63 crore

Balaxi Pharmaceuticals Ltd. (BALAXI) operates in the Trading sector, within the Trading industry.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 51.93x, which is above the benchmark median of 22.63x, a difference of +129.47%. The P/E comparison frames valuation; it is not a signal to buy or sell.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROE of 0.59%, which is below the benchmark median of 4.09%, a difference of -85.57%. Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROCE of 3.48%, which is below the benchmark median of 6.07%, a difference of -42.67%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Adani Enterprises Ltd. ADANIENT 3,71,326.11 63.38 3.71 15.07 13.3
ADITYA INFOTECH LIMITED CPPLUS 48,883.55 81.56 13.18 25.68 29.48
Aegis Logistics Ltd. AEGISLOG 46,117.27 33.59 4.41 20.71 19.76
Premier Energies Ltd. PREMIERENE 37,859.56 21.42 7.33 42.6 33.72
Redington Ltd. REDINGTON 26,807.05 14.25 2.45 13.6 18.96

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 51.93x compared with the displayed peer median of 33.59x. Peer multiples give relative context only, not a buy or sell view. Its ROE of 0.59% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 3.48% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Balaxi Pharmaceuticals Ltd. (BALAXI) has a market capitalisation of Rs 146.13 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Balaxi Pharmaceuticals Ltd.

  • Balaxi Pharmaceuticals Ltd. Share Price is up 16.4% today, with the stock trading at Rs 36.84 versus the previous close of Rs 31.65.
  • The day’s range for Balaxi Pharmaceuticals Ltd. Share Price is narrow enough to show a defined move from the opening level of Rs 31.80 to a high of Rs 36.90.
  • Balaxi Pharmaceuticals Ltd. Fundamental Analysis shows a P/E of 51.93, P/B of 0.69, ROE of 0.59%, ROCE of 3.48% and EPS of Rs 0.61.
  • Sector context keeps Balaxi Pharmaceuticals Ltd. Share Price below the trading-industry median on P/E, P/B, ROE and ROCE.
  • Peer comparison shows Balaxi Pharmaceuticals Ltd. Share Price alongside companies with much higher market capitalisation and stronger return ratios.

About Balaxi Pharmaceuticals Ltd.

Balaxi Pharmaceuticals Ltd. operates in the Trading sector and Trading industry. In this note, the company is assessed through market-cap, valuation and return metrics rather than a broad business description, because the verified numbers are the most relevant facts for today’s Balaxi Pharmaceuticals Ltd. Share Price. The latest Univest figures place the company at Rs 146.13 Cr market capitalisation, with P/E at 51.93, P/B at 0.69, ROE at 0.59, ROCE at 3.48, EPS at Rs 0.61 and book value at Rs 46.04. Dividend yield is 0%, so the current Balaxi Pharmaceuticals Ltd. Share Price is not supported by a dividend yield metric in this snapshot. For readers following Balaxi Pharmaceuticals Ltd. Stock News, the company remains best understood through its valuation and sector positioning in today’s market update.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

Why is Balaxi Pharmaceuticals Ltd. Share Price rising today?

Ans. Balaxi Pharmaceuticals Ltd. Share Price is up 16.4% today to Rs 36.84, but no company-specific catalyst is established. The move is confirmed by the latest Univest figures and should be read alongside valuation and sector context.

What is Balaxi Pharmaceuticals Ltd. Share Price today?

Ans. Balaxi Pharmaceuticals Ltd. Share Price is trading at Rs 36.84, compared with the previous close of Rs 31.65. The stock opened at Rs 31.80 and touched a high of Rs 36.90 in today’s trade.

What is the market capitalisation of Balaxi Pharmaceuticals Ltd.?

Ans. Balaxi Pharmaceuticals Ltd. has a market capitalisation of Rs 146.13 Cr. That places the Balaxi Pharmaceuticals Ltd. Share Price in a context that is above the sector median market cap but well below the sector average.

How does Balaxi Pharmaceuticals Ltd. Share Price compare with the sector?

Ans. The Balaxi Pharmaceuticals Ltd. Share Price sits against a trading-industry benchmark of 470 companies. Its P/E, P/B, ROE and ROCE are all below the sector medians on the latest Univest figures.

What is Balaxi Pharmaceuticals Ltd. P/E ratio?

Ans. Balaxi Pharmaceuticals Ltd. has a P/E ratio of 51.93. For Balaxi Pharmaceuticals Ltd. Share Price readers, that sits above the sector median of 22.63 and below the sector average of 90.95.

What is Balaxi Pharmaceuticals Ltd. P/B ratio?

Ans. Balaxi Pharmaceuticals Ltd. has a P/B ratio of 0.69 and a book value of Rs 46.04. That makes the Balaxi Pharmaceuticals Ltd. Share Price sit below book value on a simple price-to-book view.

What do ROE and ROCE show for Balaxi Pharmaceuticals Ltd.?

Ans. Balaxi Pharmaceuticals Ltd. reports ROE of 0.59% and ROCE of 3.48. These return measures suggest the Balaxi Pharmaceuticals Ltd. Share Price is rising today against a modest return profile in the latest snapshot.

Does Balaxi Pharmaceuticals Ltd. pay a dividend yield?

Ans. The dividend yield for Balaxi Pharmaceuticals Ltd. is 0. For Balaxi Pharmaceuticals Ltd. Share Price tracking, that means today’s move is not accompanied by a dividend yield contribution in the latest figures.

Track Balaxi Pharmaceuticals Ltd. Share Price on Univest

Use Balaxi Pharmaceuticals Ltd. (BALAXI) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Readers tracking Balaxi Pharmaceuticals Ltd. Share Price on Univest can monitor live price moves, valuation ratios, 52-week levels and market insights in one place. The Balaxi Pharmaceuticals Ltd. Share Price Today view is especially useful when a stock is rising without a verified catalyst. Univest also helps compare the Balaxi Pharmaceuticals Ltd. Share Price with sector benchmarks and listed peers.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply